Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England

  1. Maria Krutikov
  2. Tom Palmer
  3. Gokhan Tut
  4. Christopher Fuller
  5. Borscha Azmi
  6. Rebecca Giddings
  7. Madhumita Shrotri
  8. Nayandeep Kaur
  9. Panagiota Sylla
  10. Tara Lancaster
  11. Aidan Irwin-Singer
  12. Andrew Hayward
  13. Paul Moss
  14. Andrew Copas
  15. Laura Shallcross

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/s2666-7568(21)00282-8
  2. ScreenIT

    SciScore for 10.1101/2021.09.27.21264166: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Written informed consent was obtained from individuals in these LTCFs and where individuals were assessed as lacking capacity to consent, a nominated or personal consultee acted on their behalf.
    IRB: Ethical approval for this study was obtained from the South Central—Hampshire B Research Ethics Committee (20/SC/0238).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Time to antibody-loss: Time to antibody-loss was estimated in individuals that who could be linked to a pseudo-identifier and had at least two eligible samples separated by more than four weeks.
    antibody-loss
    suggested: None
    The date of sero-reversion was the mid-point between last antibody-positive and first antibody-negative test.
    antibody-negative test.
    suggested: None
    Software and Algorithms
    SentencesResources
    Date of sero-reversion followed the definitions outlined above according to the Abbott assay.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    All statistical analyses were performed in STATA version 16·0, with weighting and clustering acknowledged using the complex survey functions.
    STATA
    suggested: (Stata, RRID:SCR_012763)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    In common with other serological studies, our study highlights the limitations of estimating the prevalence of natural infection based on antibody titres against nucleocapsid protein. 25 Direct comparison of seroprevalence estimates between studies and countries is challenging due to variation in the timing of pandemic waves and waning immunity. The largest published prevalence study to date included over 9,000 LTCF residents from 362 LTCFs in Madrid and reported that 55·4% of residents had detectable anti-nucleocapsid antibodies following the first wave of the pandemic (June to Nov 2020), however as these estimates were unweighted and the study was limited to one region, this may not be generalisable to the national prevalence of infection.26 In England, national surveillance data from 14 June-11 July 2021 report 16·6 % weighted nucleocapsid antibody prevalence in the general population, lowest in the 70-84 age group.12 These estimates are based on samples from blood donors in the community where infection rates were likely to be lower than in LTCFs, particularly over the first pandemic wave.2 Our study also found lower seroprevalence in Independent LTCFs when compared with For-Profit chains and in larger vs smaller LTCFs, which have been widely described as risk factors for SARS-CoV-2 transmission. 1,27 Our study makes a valuable contribution to a growing body of evidence of rapid waning of nucleocapsid antibody titres following natural infection across age groups, which pr...

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    ISRCTN14447421NANA

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.09.27.21264166v1 on medRxiv